Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said ...

As someone living with PH and coexisting conditions, columnist Jen Cueva has had to learn how to deal with frustrating health setbacks.

(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

The LungFit PH device was approved ini 2022 by the U.S. Food and Drug Administration and the European Union to treat PPHN.

Cancer occurred in 18% of patients with CTEPH, and mortality rates were higher among those with cancer vs those without (28% vs 6%). Patients with chronic thromboembolic pulmonary hypertension (CTEPH) ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing ...

Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.